In summary, our study found that the active sphingolipid So(d18:1) has a good indicating ability in patients with NASH and that it can bind to HIF-2α to aggravate liver inflammation and fibrosis in NASH model mice. Here, EPAS1 is linked to metabolic dysfunction-associated steatohepatitis.